Kinase mutation-associated neurodegenerative disorders
AssigneeMemorial Sloan Kettering Cancer Center
InventorsFrederic Geissmann, Elvira Mass, Rocio Vicario
Life of this patent
Estimating the term…
Abstract
The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
Claims10
A method for treating phosphoinositide 3-kinase (PI 3-kinase)-associated neurodegenerative disease in a subject diagnosed as having, suspected as having, or at risk of having one or more mutations in one or more PI 3-kinases, comprising administering one or more of a BRAF inhibitor, a MEK inhibitor, a Ras inhibitor, and/or a CSF-1R inhibitor.
Dependencies are inferred from the claim text.